Unusual cystic lesion of the eyebrow: A case report of malignant chondroid syringoma

• Published in: Journal of stomatology, oral and maxillofacial surgery Vol. 119; no. 3; pp. 232 - 235
• Main Authors: Chauvel-Picard, J., Pierrefeu, A., Harou, O., Breton, P., Sigaux, N.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.06.2018
• Subjects: Chondroid syringoma; Dentistry; Eyelid; Reconstructive surgery; Surgical flap; Sweat gland; Sweat gland; Eyelid; Surgical flap; Chondroid syringoma; Reconstructive surgery
• ISSN: 2468-7855; 2468-7855
• DOI: 10.1016/j.jormas.2018.02.008

Malignant chondroid syringomas, also known as cutaneous malignant mixed tumors, are rare neoplasms that most frequently occur on the torso or extremities of women. Here, we present an illustrated case of a facial malignant chondroid syringoma. A 32-year-old female patient with no notable medical history presented with an approximately 1cm-wide, painless, palpably-mobile subcutaneous nodule, suggestive of a sebaceous cyst, just above the middle third of the right eyebrow. The nodule had grown steadily over six months. She had no palpable cervical lymphadenopathies. Anatomic pathology of the enucleated nodule found an adnexal sudoriparous tumor measuring 6×10mm and indicative of a malignant chondroid syringoma. Cervicofacial computed tomography and positron emission tomography scans showed no near or distant lymph node involvement. A second intervention for wide excision around the original enucleation lesion (+1cm) was validated in a multidisciplinary, cancerology-dermatology consultation. The eyebrow was reconstructed with a temporally-harvested fasciocutaneous island flap. Malignant chondroid syringomas are very rare and thus no standardized treatment has been established for them. Only 12 craniofacial localizations have been described to date. Radiation therapy and chemotherapy have not been shown effective for this malignancy, leaving only wide excision as a therapeutic option. A high and sustained (as much as 20 years after the initial diagnosis) risk of recurrence or metastasis necessitates prolonged patient follow-up.